Keywords
Last Name
Institution
Children's Mercy Kansas City
More Search Options
Menu
Home
Find People
Find Everything
About This Site
Annual Report
Export RDF
Can anthracycline therapy for pediatric malignancies be less cardiotoxic?
Fulbright JM, Huh W, Anderson P, Chandra J. Can anthracycline therapy for pediatric malignancies be less cardiotoxic? Curr Oncol Rep. 2010 Nov; 12(6):411-9.
View in:
PubMed
subject areas
Adolescent
Adult
Anthracyclines
Child
Delayed-Action Preparations
Disease Progression
Doxorubicin
Drug Administration Schedule
Drug Carriers
Drug Dosage Calculations
Drug-Related Side Effects and Adverse Reactions
Heart
Heart Diseases
Heart Failure
Humans
Iron Chelating Agents
Leukemia, Myeloid, Acute
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Randomized Controlled Trials as Topic
Razoxane
Risk Factors
Treatment Outcome
authors with profiles
Joy M. Fulbright
Can anthracycline therapy for pediatric malignancies be less cardiotoxic?